FDA Grants New RMAT Designation Humacyte Vascular Tissue Therapy

The FDA granted expedited review to Humacyte’s tissue therapy under the new Regenerative Medicine Advanced Therapy pathway — one of the first products to receive the designation established by the 21st Century Cures Act.
Source: International Pharmaceutical Regulatory Monitor